Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

ANI Pharmaceuticals (ANIP) announced results from the NEW DAY clinical trial of ILUVIEN, or fluocinolone acetonide intravitreal implant, 0.19 mg ...

ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...

In the A and B arms of the phase 3 FAME study, 956 patients with diabetic macular edema (DME) were randomized to receive either 0.5 µg/day of Iluvien (Alimera Sciences), 0.2 µg/day of Iluvien or ...

We note that the path leading to the FDA approval for Iluvien has been anything but smooth for Alimera. In Oct 2013, the company received the third Complete Response Letter (CRL) from the FDA on ...

“From a creative standpoint, the campaign was focused on bringing light to having something like Iluvien and how that would be beneficial to their lifestyle,” Hoffman said. “If you are dealing with ...

ILUVIEN is injected in the back of the patient's eye to a position that takes advantage of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle, which allows for a self ...

ATLANTA — The U.S. Food and Drug Administration has issued a complete response letter to Alimera Sciences for its investigational sustained drug delivery system Iluvien, effectively denying ...

ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis IndicationsATLANTA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera ...